Table 1.
Patient characteristics at the time of diagnosis and treatment.
| Total subjects (n = 25) | Microadenoma (n = 11) (44%) | Macroadenoma (n = 14) (56%) | P-value* | |
|---|---|---|---|---|
| Follow-up period (yr) | 3.0 (2.0, 4.1) | |||
| Gender (female) | 20/25 (80%) | 11 (55%) | 9 (45%) | 0.134 |
| Age at diagnosis (median, IQR) (yr) | 16.9 (16.3, 18.0) (range: 10.9–18.4) | 17.1 (16.7, 17.7) | 16.8 (14.3, 18.1) | 0.727 |
| Height (SDS) | 0.3 (−1.2, 0.7) | 0.3 (−0.6, 1.7) | −1.6 (0.1, 0.7) | 0.501 |
| BMI (SDS) | 0.4 (−0.2, 0.8) | 0.3 (0.1, 0.4) | 0.5 (−0.2, 1.3) | 0.434 |
| PRL at diagnosis (ng/mL) | 207.0 (116.6, 1056.5)† | 114.2 (85.6, 189.5) | 516.0 (202.8, 3567.5) | <0.001 |
| Maximum tumor diameter (mm) | 12.0 (9.0, 21.5) (range: 4–74) | 9 (7, 10) | 21 (14.3, 26.3) | <0.001 |
| Panhypopituitarism | 11/25 (44%) | 1/11 (9%) | 10/14 (71%) | 0.008 |
| Operation (TSA) | 15/25 (60%) | 3/11 (27%) | 12/14 (86%) | 0.003 |
| Immediate postoperative PRL levels | 25.0 (2.9, 83.0) | 2.7 (1.3, 2.9) | 31.7 (1.2, 1,102) | 0.031 |
| Nadir PRL level (ng/mL) | 9.4 (2.6, 34.5) | 7.5 (0.6, 33.0) | 9.7 (4.9, 43.3) | 0.373 |
| Ki-67 index | 3.1 (2.0, 5.0) | 3 (0.1, 5) | 3.4 (1.2, 16.0) | 0.536 |
| Responsiveness to DAs | 10/18 (56%) | 5/7 (71%) | 5/11 (45%) | 0.436 |
| At age of first use with CAB (yr) | 17.5 (16.3, 19.6) | 18.4 (17.2, 19.6) | 16.6 (13.5, 19.5) | 0.228 |
| CAB peak (mg/wk) | 1.5 (1.0, 2.0) | 1.0 (1.0, 1.9) | 2.0 (1.1, 2.4) | 0.130 |
| CAB duration (yr) | 1.1 (0.1, 2.2) | 0.3 (0.1, 1.1) | 1.8 (0.4, 2.7) | 0.081 |
| BRC peak (mg/day) | 30 (3.4, 105.0) | 7.5 | 52.5 (3.1, 140) | 1.000 |
| BRC duration (yr) | 1.9 (1.1, 7.6) | 0.9 | 2.1 (1.4, 8.2) | 0.333 |
Data are expressed as median (IQR) or mean ± sd.
BMI, body mass index; IQR, interquartile range; SD, standard deviation; PRL, prolactin; TSA, transphenoidal approach; DAs, dopamine agonists; CAB, cabergoline; BRC, bromocriptine.
*
Significant association was classified as P < 0.05.
†
Reference range of serum prolactin: 72–10,000 ng/mL.